Date:1/23/2012

ievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the ability for the Company to derive business partnerships or future revenue streams using the Aethlon ADAPT™ system including the ability to introduce a targeted breast cancer therapy known as HER2osome™, there is no assurance that FDA will approve the initiation of the company's clinical programs or provide market clearance of the company's products, the ability to achieve the goals set out in the DARPA contract, future human studies of the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer therapies, the company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.

Contacts:

James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com

Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com

John P. Salvador
Director, Communications
858.459.7800 x307
jps@aethlonmedical.com'/>"/>

SOURCE Aethlon Medical, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related biology technology :

1. Aethlon Medical to Present at the Wall Street Analyst Forum 22nd Annual Investor Conference
2. Aethlon Medical Announces Washington, DC Shareholder Presentation
3. Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board
4. Aethlon Medical to Present at LD MICRO Conference on December 3, 2009
5. Aethlon Medical, Inc. Announces Annual Meeting Results
6. Aethlon Medical Announces Data Supported Strategy to Increase Hepatitis-C (HCV) Cure Rates
7. UH Case Medical Center Offers New Therapy for Gynecologic Cancer Patients
8. First Choice Rehabilitation Specialists Joins Select Medical
9. inVentiv Health to Acquire SDI Promotional and Medical Audit Businesses From IMS Health
10. Scott Brooks Joins Regenesis Biomedical as Chief Operating Officer
11. Saladax Biomedical, Inc. Issued Six Patents Containing Broad Claims in the Immunoassay Space